Old Web
English
Sign In
Acemap
>
Paper
>
Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase
Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase
2017
Rüdiger Hehlmann
Michael Lauseker
Susanne Saussele
Markus Pfirrmann
Stefan W. Krause
Hans Jochem Kolb
Andreas Neubauer
Dieter K. Hossfeld
Christoph Nerl
Alois Gratwohl
Gabriela M. Baerlocher
Dominik Heim
Tim H. Bruemmendorf
Alice Fabarius
Claudia Haferlach
Brigitte Schlegelberger
Martin C. Müller
Sabine Jeromin
Ulrike Proetel
Katharina Kohlbrenner
Astghik Voskanyan
Sebastien Rinaldetti
Wolfgang Seifarth
Birgit Spiess
Leopold Balleisen
Maria E Goebeler
Mathias Hänel
Anthony D. Ho
Jolanta Dengler
C. Falge
Lothar Kanz
Claus-Henning Köhne
Andreas Burchert
Michael Kneba
Frank Stegelmann
C. A. Köhne
Hans Walter Lindemann
C.F. Waller
Michael Pfreundschuh
Karsten Spiekermann
Wolfgang E. Berdel
Lutz P. Müller
Matthias Edinger
Jiri Mayer
Dietrich W. Beelen
Martin Bentz
Hartmut Link
Bernd Hertenstein
R. Fuchs
Martin Wernli
F. Schlegel
Rudolph Schlag
M. de Wit
Lorenz Trümper
H Hebarth
M Hahn
Jörg Thomalla
Christof Scheid
Philippe Schafhausen
Walter Verbeek
Michael J. Eckart
Winfried Gassmann
Antonio Pezzutto
Michael Schenk
Peter Brossart
Thomas Geer
Stephan Bildat
Erhardt Schäfer
Andreas Hochhaus
Joerg Hasford
Keywords:
Progression-free survival
Blast Phase
Comorbidity
imatinib mesylate
Oncology
Internal medicine
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
4
Citations
NaN
KQI
[]